Literature DB >> 21660643

Preoperative transabdominal ultrasonography (US) prior to laparoscopic Roux-en-Y gastric bypass (LRYGBP) and laparoscopic sleeve gastrectomy (LSG) in the first 100 operations. Was it beneficial and reliable during the learning curve?

Nabil Jaser1, Harri Mustonen, Jaakko Pietilä, Anne Juuti, Marja Leivonen.   

Abstract

BACKGROUND: Preoperative ultrasonography (US) prior to laparoscopic Roux-en-Y gastric bypass (LRYGBP) aimed to find possible gallstones. The aim of this study was to evaluate the reliability of the US in evaluating the size and consistency of the left lobe of the liver.
METHODS: One hundred LRYGBP and LSG were performed in our new bariatric surgery unit by two surgeons. All patients underwent preoperative US to evaluate the size and consistency of the left lobe of the liver. A consultant radiologist reviewed the US findings, which were then compared to the intraoperative findings.
RESULTS: The mean preoperative body mass index was 49. All patients had co-morbidities. The intraoperative evaluation showed an enlarged left lobe of the liver in 23 patients, whereas the US found enlargement only in eight patients, but revealed eight false positives. In the intraoperative evaluation, fatty liver was observed in five patients, only four of whom were shown in the US, but US revealed 77 false positives. In evaluating the size of the left lobe, US had 35% sensitivity, 90% specificity, 65% false negative rate (FNR) and 10% false positive rate (FPR). In evaluating the consistency, US had 80% sensitivity, 18% specificity, 20% FNR and 82% FPR.
CONCLUSION: Preoperative US is unreliable in evaluating the size and consistency of the left lobe of the liver prior to LRYGBP and LSG and has limited prognostic value for surgical complications and complexity of surgery.

Entities:  

Mesh:

Year:  2012        PMID: 21660643     DOI: 10.1007/s11695-011-0416-z

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  35 in total

1.  Overweight and obesity worldwide now estimated to involve 1.7 billion people.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2003-06       Impact factor: 4.129

2.  Preoperative low energy diet diminishes liver size.

Authors:  Robert J Fris
Journal:  Obes Surg       Date:  2004-10       Impact factor: 4.129

3.  Change in liver size and fat content after treatment with Optifast very low calorie diet.

Authors:  Mark C Lewis; Madeleine L Phillips; John P Slavotinek; Lilian Kow; Campbell H Thompson; Jim Toouli
Journal:  Obes Surg       Date:  2006-06       Impact factor: 4.129

4.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

5.  Meta-analysis: surgical treatment of obesity.

Authors:  Melinda A Maggard; Lisa R Shugarman; Marika Suttorp; Margaret Maglione; Harvey J Sugerman; Harvey J Sugarman; Edward H Livingston; Ninh T Nguyen; Zhaoping Li; Walter A Mojica; Lara Hilton; Shannon Rhodes; Sally C Morton; Paul G Shekelle
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

6.  A decade of change in obesity surgery. National Bariatric Surgery Registry (NBSR) Contributors.

Authors:  E E Mason; S Tang; K E Renquist; D T Barnes; J J Cullen; C Doherty; J W Maher
Journal:  Obes Surg       Date:  1997-06       Impact factor: 4.129

7.  Bariatric surgery worldwide 2003.

Authors:  Henry Buchwald; Stanley E Williams
Journal:  Obes Surg       Date:  2004-10       Impact factor: 4.129

8.  Factors determining conversion from laparoscopic to open Roux-en-Y gastric bypass.

Authors:  Michael L Schwartz; Raymond L Drew; Marilyn Chazin-Caldie
Journal:  Obes Surg       Date:  2004-10       Impact factor: 4.129

9.  Sleeve gastrectomy in the high-risk patient.

Authors:  Nahid Hamoui; Gary J Anthone; Howard S Kaufman; Peter F Crookes
Journal:  Obes Surg       Date:  2006-11       Impact factor: 4.129

10.  Laparoscopic Roux-en-Y gastric bypass for morbid obesity: results of our learning curve in 100 consecutive patients.

Authors:  Enrique Stoopen-Margain; Rafael Fajardo; Nayví España; Rosa Gamino; Jorge González-Barranco; Miguel F Herrera
Journal:  Obes Surg       Date:  2004-02       Impact factor: 4.129

View more
  5 in total

1.  Role of Routine Abdominal Ultrasound Before Bariatric Surgery: Review of 937 Patients.

Authors:  Bassem M Abou Hussein; Ali Khammas; Maryam Makki; Marwah Makki; Usama Al Bastaki; Alya Al Mazrouei; Faisal S Badri
Journal:  Obes Surg       Date:  2018-09       Impact factor: 4.129

2.  Four Weeks of Preoperative Omega-3 Fatty Acids Reduce Liver Volume: a Randomised Controlled Trial.

Authors:  Nathalie Bakker; Rick S van den Helder; Remy W F Geenen; Michiel A Hunfeld; Huib A Cense; Ahmet Demirkiran; Alexander P J Houdijk
Journal:  Obes Surg       Date:  2019-07       Impact factor: 4.129

3.  Routine trans-abdominal ultrasonography before laparoscopic sleeve gastrectomy: the findings.

Authors:  Sulaiman Almazeedi; Salman Al-Sabah; Dheidan Alshammari
Journal:  Obes Surg       Date:  2014-03       Impact factor: 4.129

4.  Different surgical approaches in laparoscopic sleeve gastrectomy and their influence on metabolic syndrome: A retrospective study.

Authors:  Hady Razak Hady; Magdalena Olszewska; Mikolaj Czerniawski; Dawid Groth; Inna Diemieszczyk; Patrycja Pawluszewicz; Adam Kretowski; Jerzy Robert Ladny; Jacek Dadan
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

5.  Gender-related metabolic outcomes of laparoscopic sleeve gastrectomy in 6-month follow-up.

Authors:  Dawid Groth; Paulina Woźniewska; Magdalena Olszewska; Piotr Zabielski; Jerzy R Ładny; Jacek Dadan; Anna Zalewska; Agnieszka Błachnio-Zabielska; Inna Diemieszczyk; Adam Krętowski; Hady Razak Hady
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2019-07-22       Impact factor: 1.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.